BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that it
has signed a letter of intent establishing ICON (ICON; NASDAQ: ICLR) as the
global clinical research organization (CRO) for the Company's ongoing pivotal
phase II/III clinical trial for MBP8298 for the treatment of multiple
sclerosis.
